Xeris Biopharma Holdings, Inc. (XERS)
NMS – Real Time Price. Currency in USD
8.40
+0.01 (0.18%)
Market open: Aug 12, 2026, 2:23 PM EDT
8.27
-0.12 (-1.43%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Find any stock by ticker or company name

NMS – Real Time Price. Currency in USD
8.40
+0.01 (0.18%)
Market open: Aug 12, 2026, 2:23 PM EDT
8.27
-0.12 (-1.43%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
No Data
There are no news for this stock.
Total debt $289.4M significantly exceeds cash reserves ($121.7M), raising financial stability concerns
Total current assets $274.8M exceed Total current liabilities $189.6M, highlighting excellent liquidity
Debt-to-equity ratio (-29.7) is well below the industry average (-0.8), showcasing prudent financial management
Interest coverage ratio (0.7x) is dangerously low, suggesting debt repayment risks
The company generates positive free cash flow $8.1M, supporting its financial health
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 1.45 | 2.52 | 7.0 | |
| Quick ratio | 1.02 | 1.78 | 7.0 | |
| Debt to Equity | N/A | -0.80 | 1.0 | |
| Debt to Assets | 0.70 | 0.73 | 3.0 | |
| Interest coverage | 0.74 | -13.90 | 3.0 | |
| Weighted average score | 4.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 110M | 164M | 203M | 292M | 335M |
| Gross Profit | 77M | 124M | 155M | 238M | 280M |
| Operating Income | -80M | -44M | -34M | 25M | 37M |
| Net Income | -95M | -62M | -55M | 554K | -17M |
| EBITDA | -68M | -31M | -21M | 38M | 49M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 36.55 | N/A | 5.5 |
| Next quarter | 28.86 | -13.33 | 5.5 |
| Current year | 32.77 | -385.1 | 5.5 |
| Next year | 24.06 | 4029.63 | 10 |
| Weighted average score | 6.6 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 10.79 | -1492.16 | -1899.99 | -15.61 | 2.5 |
| Y/Y | 28.74 | -1513.11 | -1699.99 | 8403.09 | 5.5 |
| 3y average | 38.76 | 49.05 | 51.45 | 83.33 | 10 |
| 5y average | 76.26 | 27.08 | 47.35 | 44.72 | 10 |
| Weighted average score | 7.0 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |